MedTrace Logo

Randomized Controlled Trial of Intravenous Magnesium Sulfate Versus Terbutaline for Children in the Management of Acute Exacerbation of Asthma

NCT06626620 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2024-10-04

No results posted yet for this study

Summary

This study aimed to fill this gap by comparing the effectiveness of intravenous magnesium sulfate versus terbutaline in children with acute asthma exacerbations, providing evidence-based guidance for clinicians in emergency settings.

Conditions

  • Acute Exacerbation of Asthma

Interventions

DRUG

Magnesium Sulphate infusion

Received IV magnesium sulfate (50 mg/kg up to a maximum dose of 2 g) administered over 20 minutes

DRUG

Terbutaline Infusion

Received IV terbutaline (10 mcg/kg bolus followed by a continuous infusion of 0.4 mcg/kg/min) for up to 4 hours

Sponsors & Collaborators

  • Nishtar Medical University

    collaborator OTHER

  • Muhammad Aamir Latif

    lead OTHER

Principal Investigators

  • Arif Zulqarnain, FCPS · Department of Pediatrics, Nishtar Hospital, Multan, Pakistan

  • Muhammad Salman, FCPS · Department of Pediatrics, Nishtar Hospital, Multan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2024-09-30
Completion
2024-09-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06626620 on ClinicalTrials.gov